LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Buparlisib | 10 | uM | LJP5 | 72 | hr | 868 | 661 | 3410 | 0.1935 | -0.1307 |
MDA-MB-231 | XL147 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3749 | 3410 | 1.1007 | 1.0998 |
MDA-MB-231 | XL147 | 0.12 | uM | LJP5 | 72 | hr | 868 | 3671 | 3410 | 1.0766 | 1.0764 |
MDA-MB-231 | XL147 | 0.37 | uM | LJP5 | 72 | hr | 868 | 3659 | 3410 | 1.0735 | 1.0735 |
MDA-MB-231 | XL147 | 1.11 | uM | LJP5 | 72 | hr | 868 | 3805 | 3410 | 1.1168 | 1.1156 |
MDA-MB-231 | XL147 | 3.33 | uM | LJP5 | 72 | hr | 868 | 3611 | 3410 | 1.0594 | 1.0596 |
MDA-MB-231 | XL147 | 10 | uM | LJP5 | 72 | hr | 868 | 3316 | 3410 | 0.9734 | 0.9732 |
MDA-MB-231 | Y39983 | 0.04 | uM | LJP6 | 72 | hr | 868 | 3238 | 3556 | 0.9081 | 0.9028 |
MDA-MB-231 | Y39983 | 0.12 | uM | LJP6 | 72 | hr | 868 | 3097 | 3556 | 0.8692 | 0.8642 |
MDA-MB-231 | Y39983 | 0.37 | uM | LJP6 | 72 | hr | 868 | 2848 | 3556 | 0.7992 | 0.7883 |
MDA-MB-231 | Y39983 | 1.11 | uM | LJP6 | 72 | hr | 868 | 2552 | 3556 | 0.7169 | 0.6969 |
MDA-MB-231 | Y39983 | 3.33 | uM | LJP6 | 72 | hr | 868 | 2074 | 3556 | 0.5822 | 0.5308 |
MDA-MB-231 | Y39983 | 10 | uM | LJP6 | 72 | hr | 868 | 573 | 3556 | 0.1611 | -0.1852 |
MDA-MB-231 | Nintedanib | 0.04 | uM | LJP6 | 72 | hr | 868 | 3852 | 3556 | 1.0802 | 1.0721 |
MDA-MB-231 | Nintedanib | 0.12 | uM | LJP6 | 72 | hr | 868 | 3640 | 3556 | 1.0224 | 1.0203 |
MDA-MB-231 | Nintedanib | 0.37 | uM | LJP6 | 72 | hr | 868 | 3503 | 3556 | 0.9838 | 0.9824 |
MDA-MB-231 | Nintedanib | 1.11 | uM | LJP6 | 72 | hr | 868 | 3044 | 3556 | 0.8555 | 0.8516 |
MDA-MB-231 | Nintedanib | 3.33 | uM | LJP6 | 72 | hr | 868 | 2488 | 3556 | 0.6989 | 0.6757 |
MDA-MB-231 | Nintedanib | 10 | uM | LJP6 | 72 | hr | 868 | 641 | 3556 | 0.1802 | -0.1394 |
MDA-MB-231 | Foretinib | 0.04 | uM | LJP5 | 72 | hr | 868 | 3236 | 3410 | 0.9490 | 0.9474 |
MDA-MB-231 | Foretinib | 0.12 | uM | LJP5 | 72 | hr | 868 | 2270 | 3410 | 0.6661 | 0.6279 |
MDA-MB-231 | Foretinib | 0.37 | uM | LJP5 | 72 | hr | 868 | 1463 | 3410 | 0.4291 | 0.3026 |
MDA-MB-231 | Foretinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 1337 | 3410 | 0.3923 | 0.2448 |
MDA-MB-231 | Foretinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1389 | 3410 | 0.4072 | 0.2682 |
MDA-MB-231 | Foretinib | 10 | uM | LJP5 | 72 | hr | 868 | 635 | 3410 | 0.1864 | -0.1471 |